December 10, 2024 10:08 AM EST
R&D

Ear­ly da­ta sug­gest Arv­inas, Pfiz­er could com­bine their breast can­cer drug with Lil­ly’s Verzenio

Elizabeth Cairns

Senior biopharma journalist

Pfiz­er and its part­ner Arv­inas may have land­ed on a CDK4/6 in­hibitor to use in com­bi­na­tion with their oral es­tro­gen re­cep­tor de­grad­er in breast can­cer …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

Bio­gen of­fers to buy out strug­gling neu­ro part­ner Sage Ther­a­peu­tics

Chas­ing the next wave of obe­si­ty drugs, Met­sera files for an IPO

Four biotechs emerge with $800M and in-li­censed as­sets on Fri­day

Up­dat­ed: CDER Di­rec­tor Pa­trizia Cavaz­zoni to step down ahead of Trump pres­i­den­cy

Ex­clu­sive: Mod­er­na's for­mer top sci­en­tist has a new start­up us­ing AI to im­prove mR­NA ther­a­pies

Post-Hoc: Big Phar­ma is los­ing the AI tal­ent war

A service from the Financial Times